EraCal Therapeutics
EraCal Therapeutics develops small molecule drugs for obesity and metabolic disorders using a phenotypic drug discovery platform based on zebrafish technology. The company's lead program, Era-107, is a selective appetite suppressor designed to measure food intake and energy expenditure at scale. Their pipeline also includes programs for appetite stimulants and treatments for cardiometabolic diseases through collaborations with pharmaceutical partners.
Biotech
Healthcare
Pharmaceuticals
Funding summary
- Total raised
- €0
- Funding rounds
- 1
Investors in EraCal Therapeutics
Investors on record for EraCal Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like EraCal Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors